Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic bronchoscopy

• Published in: Journal of antimicrobial chemotherapy 2002-12, Vol.50 (6), p.1011-1015
• Main Authors: Ziglam, Hisham M., Baldwin, David R., Daniels, Ian, Andrews, Jenny M., Finch, Roger G.
• Format: Article
• Language: English
• Subjects: Administration, Oral; Adult; Aged; Antibacterial agents; Antibiotics. Antiinfectious agents. Antiparasitic agents; Area Under Curve; Biological and medical sciences; Bronchoscopy - methods; Dose-Response Relationship, Drug; Female; Fiber Optic Technology; Humans; Macrophages, Alveolar - drug effects; Macrophages, Alveolar - metabolism; Male; Medical sciences; Middle Aged; Patients - statistics & numerical data; Pharmacology. Drug treatments; Respiratory Mucosa - drug effects; Respiratory Mucosa - metabolism; Rifampin - administration & dosage; Rifampin - blood; Rifampin - pharmacokinetics
• ISSN: 0305-7453; 1460-2091; 1460-2091
• DOI: 10.1093/jac/dkf214

The concentrations of rifampicin in epithelial lining fluid (ELF), human alveolar macrophages (AM), bronchial mucosal biopsies and serum were measured after a single oral dose of 600 mg rifampicin from 15 patients undergoing fibre-optic bronchoscopy. The samples of ELF, AM, the bronchial mucosal biopsies and serum were obtained ∼2–5 h after dosing. The mean concentrations (mean ± standard error) were 5.25 mg/L (±0.67) in ELF, 7.93 mg/kg (±1.61) in bronchial biopsies, 15.48 mg/L (±1.41) in serum and 251.8 mg/L (±65.92) in alveolar macrophages. These site concentrations exceeded the MIC90 for common respiratory pathogens including Mycobacterium tuberculosis and support the observed clinical efficacy of rifampicin in the treatment of a wide range of respiratory tract infections.